People: Rexahn Pharmaceuticals Inc (RNN)
RNN on American Stock Exchange
0.35USD
21 May 2013
0.35USD
21 May 2013
Price Change (% chg)
$0.04 (+12.80%)
$0.04 (+12.80%)
Prev Close
$0.31
$0.31
Open
$0.33
$0.33
Day's High
$0.35
$0.35
Day's Low
$0.31
$0.31
Volume
1,222,983
1,222,983
Avg. Vol
356,839
356,839
52-wk High
$0.81
$0.81
52-wk Low
$0.28
$0.28
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Chang Ahn |
60 | 2013 | Chairman of the Board, Chief Scientist |
Rakesh Soni |
56 | 2009 | President, Chief Operating Officer |
Peter Suzdak |
2013 | Chief Executive Officer | |
Tae Heum Jeong |
41 | 2012 | Chief Financial Officer, Secretary |
Charles Beever |
59 | 2006 | Independent Director |
Peter Brandt |
56 | 2010 | Independent Director |
Kwang Soo Cheong |
51 | 2006 | Independent Director |
Richard Kivel |
45 | 2010 | Independent Director |
David McIntosh |
53 | 2005 | Independent Director |
Stephanie Ascher |
IR Contact Officer |
Biographies
| Name | Description |
|---|---|
Chang Ahn |
Dr. Chang H. Ahn is Chairman of the Board, Chief Scientist of Rexahn Pharmaceuticals Inc. He has been appointed as the Chief Scientist and is no longer Chief Executive Officer of the company effective February 4, 2013. Dr. Ahn has served as Chairman of the Board of Directors, Chief Executive Officer and a Director since May 2005. Dr. Ahn served as Chairman and Chief Executive Officer of Rexahn, Corp from its incorporation in March 2001 to May 2005. From 1988 to 2001, Dr. Ahn held dual positions as both Regulatory Pharmacologist and Lab Head at the FDA’s Center for Drug Evaluation and Research. Prior to joining the FDA in 1988, Dr. Ahn carried out cancer research at the National Cancer Institute, as well as at Emory University’s School of Medicine. In 2003 and 2004, Dr. Ahn organized and chaired the U.S.-Korea Bio Business and Partnership Forum, for which the State of Maryland and Montgomery County are partners. He also served as president of the Society of Biomedical Research from 2000 to 2003. Dr. Ahn holds a Ph.D. in pharmacology from Ohio State University. He also holds two B.S. degrees in pharmacy from Creighton University and Seoul National University. |
Rakesh Soni |
Mr. Rakesh Soni is President, Chief Operating Officer of Rexahn Pharmaceuticals Inc., since August 2009. Mr. Soni served as Chief Business Officer from July 2008 to August 2009. He joined Rexahn with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held several leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, he has held a variety of management positions at Novartis and Schering-Plough. He is a member of the Healthcare Marketing Council, the Medical Marketing Association and Licensing Executives Society. Mr. Soni has a B.S. from University of Wisconsin, Madison and an M.B.A. from Fairleigh Dickinson University. |
Peter Suzdak |
Dr. Peter D. Suzdak has been appointed as the Chief Executive Officer of Rexahn Pharmaceuticals, Inc., effective February 4, 2013. He has served as Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule inhibitors to treat pulmonary and vascular disorders. Prior to that he was co-Founder, founding Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to that he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut. |
Tae Heum Jeong |
Mr. Tae Heum Jeong is Chief Financial Officer, Secretary of Rexahn pharmaceuticals Inc. He resigned as Director effective June 18, 2012. Mr. Jeong has served as Chief Financial Officer and Secretary since May 2005. Mr. Jeong served as Chief Financial Officer of Rexahn, Corp from December 2002 to May 2005. From 1997 to November 2002, Mr. Jeong served as a senior investment manager at Hyundai Venture Investment Corporation, a venture capital firm where he managed the biotech investment team. He was also a committee member of the Industrial Development Fund of Korea’s Ministry of Commerce, Industry and Energy from 2000 to 2002. Mr. Jeong holds an M.S. in Finance from Johns Hopkins University, and a B.S. and an M.S., in Chemistry, from POSTECH. |
Charles Beever |
Mr. Charles Beever is Independent Director of Rexahn Pharmaceuticals Inc., since May 2006. He is a Vice President of Booz & Company, Inc., one of the successor companies to Booz Allen & Hamilton, Inc. (“Booz Allen”) where he was a Vice President from October 1993 to July 2008. Prior to being elected Vice President, he served as staff member and Engagement Manager at Booz Allen from January 1984 to October 1993. Prior to joining Booz Allen, Mr. Beever served as Plant Production Manager from October 1981 to January 1984, Industrial Engineering Manager from June 1979 to October 1981 and Production Supervisor from July 1978 to June 1979 at McGraw-Edison Company. Mr. Beever holds a B.A. in Economics from Haverford College, where he was elected to Phi Beta Kappa, and an M.B.A. from the Harvard Graduate School of Business Administration. |
Peter Brandt |
Mr. Peter C. Brandt is Independent Director of Rexahn Pharmaceuticals Inc., since September 2010. He was most recently President and Chief Executive Officer of Noven Pharmaceuticals. Prior to Noven, he spent 28 years at Pfizer. He served as Pfizer’s President – U.S. Pharmaceuticals Operations. Prior to running the U.S. operations, he led the Latin American Pharmaceuticals Operations, as well as the following Pfizer Worldwide Pharmaceuticals functions: Finance, Information Technology, Planning and Business Development. He also oversaw the operations of Pfizer’s care management subsidiary, Pfizer Healthcare Solutions. Mr. Brandt holds a B.A. from the University of Connecticut and an M.B.A. from the Columbia School of Business. |
Kwang Soo Cheong |
Dr. Kwang Soo Cheong is Independent Director of Rexahn Pharmaceuticals Inc., since May 2006. He is a faculty member at the Department of Finance of the Johns Hopkins University Carey Business School (Assistant Professor: 2001-2005; Associate Professor: 2006 to date). Dr. Cheong was an Assistant Professor of Economics at the University of Hawaii from 1994 to 2001, and he was a lecturer at the Department of Economics of Stanford University from 1993 to 1994. During the summer of 1995, Dr. Cheong was a Visiting Fellow in the Taxation and Welfare Division at the Korea Development Institute in Korea. Dr. Cheong holds a B.A. in Economics and an M.A. in Economics from Seoul National University, and a Ph.D. in Economics from Stanford University. |
Richard Kivel |
Mr. Richard Kivel is Independent Director of Rexahn Pharmaceuticals Inc., since September 2010. He is currently a Senior Manager at Bridgewater Associates. He presently serves as Chairman of Rhapsody Biologics, a biotech company focused in the field of vaccine development, with offices in the US and Singapore. Prior to this, he served as Chief Executive Officer of TheraGenetics, a UK-based genetic diagnostics company developing pharmacogenetic tests to improve the treatment of Central Nervous System (CNS) disorders. He also serves as Chairman of the global Board of Directors of the MIT Enterprise Forum and is a member of the MIT Alumni Association Board. Additionally, he is a member of the Board of Trustees of Fundación de la Innovación Bankinter in Madrid, Spain. Mr. Kivel holds a B.A degree from American International College, an M.S in management from Boston College, and is a graduate of University of Pennsylvania Executive Program: Drug Discovery, Therapeutics & New Innovations. |
David McIntosh |
Mr. David M. McIntosh is Independent Director of Rexahn Pharmaceuticals Inc., since May 2005. Mr. McIntosh served as a director of Rexahn, Corp. from March 2004 to May 2005. He has been a partner at Mayer Brown LLP (law firm) since 2001. He is currently on a leave of absence from Mayer Brown, LLP as a candidate for the U.S. House of Representatives. Mr. McIntosh was a member of the United States House of Representatives, representing the 2nd District of Indiana from 1995 to 2001. From 1993 to 1994, he was a director of the Hudson Institute Competitiveness Center. He served on President George H.W. Bush’s Council on Competitiveness as Executive Director from 1989 to 1993. He also served as the Special Assistant to President Reagan for Domestic Affairs from 1987 to 1989 and was the Special Assistant to the Attorney General of the United States from 1986 to 1987. Mr. McIntosh received a B.A. from Yale College and a J.D. from the University of Chicago Law School. |
Stephanie Ascher |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Chang Ahn |
475,540 |
Rakesh Soni |
406,171 |
Peter Suzdak |
-- |
Tae Heum Jeong |
261,770 |
Charles Beever |
-- |
Peter Brandt |
-- |
Kwang Soo Cheong |
-- |
Richard Kivel |
-- |
David McIntosh |
-- |
Stephanie Ascher |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Chang Ahn |
0 | 0 |
Rakesh Soni |
0 | 0 |
Peter Suzdak |
0 | 0 |
Tae Heum Jeong |
0 | 0 |
Charles Beever |
0 | 0 |
Peter Brandt |
0 | 0 |
Kwang Soo Cheong |
0 | 0 |
Richard Kivel |
0 | 0 |
David McIntosh |
0 | 0 |
Stephanie Ascher |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
AHN CHANG HO |
25,000 | $0.00 |
KIVEL RICHARD |
2,500 | $1.04 |
BRANDT PETER C |
55,100 | $1.22 |
BRANDT PETER C |
13,300 | $1.22 |
BRANDT PETER C |
6,600 | $1.21 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
